VEGFA and neoplasm: In terms of informing biomarker selection for anti‐angiogenic therapies, Motzer et al. applied multi‐omics (transcriptomics and genomics) to the analysis of 702 pretreatment renal cell carcinoma tumor samples and identified disease molecular subtypes that are strongly associated with differential clinical outcomes to combined anti‐VEGF (bevacizumab) plus anti‐PDL1 (atezolizumab) versus sunitinib alone (Motzer et al., 2020).